{"name":"NeuroVive Pharmaceutical AB","slug":"neurovive-pharmaceutical-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NeuroSTAT®","genericName":"NeuroSTAT®","slug":"neurostat","indication":"Acute ischemic stroke","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Sandimmune® Injection","genericName":"Sandimmune® Injection","slug":"sandimmune-injection","indication":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)","status":"marketed"}]}],"pipeline":[{"name":"NeuroSTAT®","genericName":"NeuroSTAT®","slug":"neurostat","phase":"marketed","mechanism":"NeuroSTAT® protects mitochondrial function and reduces neuronal damage by stabilizing the inner mitochondrial membrane during ischemic stress.","indications":["Acute ischemic stroke","Cardiac surgery-associated neurological complications"],"catalyst":""},{"name":"Sandimmune® Injection","genericName":"Sandimmune® Injection","slug":"sandimmune-injection","phase":"marketed","mechanism":"Sandimmune (cyclosporine) suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing immune-mediated rejection and inflammatory responses.","indications":["Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)","Severe active rheumatoid arthritis","Severe psoriasis","Nephrotic syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQUTlfRkFoWThxZVkyNWJlZFJhTXlIQjhHOXlzcXJOdjlEdzNSdnViWTd5MVlFMi1DV2VlMnRtQkx2LWFwRmEtd3FpNDh4dlpmUFNvM2tiOHRjalRESTFFbC1VTjhCZDFfTExDRkQ0SzBpMW9rb2tsQVdjeG1uTFlQS3l6dkFDQUlHZ1dFRWNNMGFocjAzanlsa2t0blI?oc=5","date":"2025-11-07","type":"trial","source":"Market Data Forecast","summary":"Europe Blood Brain Barrier Technologies Market, Size,Share,2033 - Market Data Forecast","headline":"Europe Blood Brain Barrier Technologies Market, Size,Share,2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQRGNXSG5INXIydTEybE5Dd1lzOHd0a2hhbW9xZDUzY1lFNG10X1R2Z3BYVWFEUW00dDEyVWI2Y1hBbVZNTzVaY1FnUzV0cXN4aUNLSThad3VzV1dYNDktN3RGTzlIbVZJeEczNDZ1TW5YYXlEOGVWTzZyVWptbGp6U2NFMnB2a293ZldiNEtYVzZEd0tJZUlUVnpld21sN3MzdEE?oc=5","date":"2025-07-31","type":"pipeline","source":"BioSpace","summary":"Mitochondrial DNA Market to Reach USD 687.99 Million by 2034 - BioSpace","headline":"Mitochondrial DNA Market to Reach USD 687.99 Million by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPeFRtZ1F1SjR5eWEzM1plMkpmRFFDdkp2cTZueGNzM2F0Vy1WNXJTbzRMX09OeU10WGU3dWFEMW9ZRFd3NUJrXzdJSE0yMXYyVzZ6NV9pSzhMTXZLTGNKMmhXSEpHZmQyYldzcmNQek5qLVE5UzJOenc2cnZjLUtvajY3cXR4Z2JsakJITw?oc=5","date":"2025-04-11","type":"pipeline","source":"Future Market Insights","summary":"Mitochondrial-based Therapeutics Market Size & Trends 2035 - Future Market Insights","headline":"Mitochondrial-based Therapeutics Market Size & Trends 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE94bTdxWkZRbU5tMnplVy05RzdsVS1hSXVGNHExSk04bFl2TGtVbE9DcEFIaTdhandRc2Yyb3F3VU5yNk9LZk5yNHFFU3VUeERvN21STW1BdElIR2poUl9nZ0ttUFQ3RjVnU3c?oc=5","date":"2022-07-20","type":"pipeline","source":"Wiley Online Library","summary":"Qualitative exploration of the lived experience of adults diagnosed with primary mitochondrial disease - Wiley Online Library","headline":"Qualitative exploration of the lived experience of adults diagnosed with primary mitochondrial disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOazBGaWZyWXRBMWlFQlQ1RWhaMHdRdUp4ekN3Zkk4eE5pRzI4UTJkS2JGcjR3UUNPdEFoYmMybnNWODZMOVduaGVzUk5iUExhRzJKQzA2VTBiRnoyeVIxZC1FTC13QXpBQ05WN01lUmRaN2RXUkpRMGlQWk13Mlp1NlllWldxUUdTWlF1TG5OY1lmM0NqSXYyVWEzY25RbVF1Z0ltaTVn?oc=5","date":"2017-12-04","type":"pipeline","source":"BioPharma Dive","summary":"Astellas picks up Mitobridge for rare mitochondrial diseases - BioPharma Dive","headline":"Astellas picks up Mitobridge for rare mitochondrial diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPTUdKYi16WlJHYnhXOWtyNU5UUGNPaXdVRUJVT3pmdWRaV3BnajMwajlGejAzbGttTm1xQWxPb1ltdzlNZDh1aG1DZkRIeUJkMnU3MTh6YlpDWVRFUmRtNmxYSHRhd0luT3lCbGJObm1QcGdlTnF3bDJCVnJpbHVYNE4tM2VZTzJ5REt1aUhKOTF2T0s4ODh3dmEtUnVLdGhMUk0zYnlLbw?oc=5","date":"2017-10-04","type":"pipeline","source":"Cision News","summary":"NeuroVive appoints Daniel Schale as Director of Communications - Cision News","headline":"NeuroVive appoints Daniel Schale as Director of Communications","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}